While the commercial position of Pfizer Inc./BioNTech SE’s and Moderna, Inc.’s COVID-19 vaccines would strengthen if it is recommended that people who received the initial two-dose vaccination series of BNT162b2 or mRNA-1273 get boosters, the US Food and Drug Administration’s expansion of the vaccines’ emergency use authorizations to include third shots for certain vulnerable people accounts for only a very small number of patients. But as variants of concern continue spreading, Moderna may have an upper hand, with data showing strong efficacy against the Delta strain, though those results come with certain caveats.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?